Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02097745 · ClinicalTrials.gov registry record · Phase 3
A Study of the Efficacy and Safety of Re-treatments With Rituximab in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-tnfa Therapies
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 341
- Enrollment target
NCT02097745 is a Phase 3 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 341 participants.
The verdict
NCT02097745, a Phase 3 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 341 participants
- Enrollment target
Study Summary
This study will assess the long-term safety and efficacy of repeating treatment with MabThera, in combination with methotrexate and steroids, in patients who were previously randomized into MabThera study WA17042. The anticipated time on study treatment is until Mabthera is available on the local market and the target sample size is 100-500 individuals.
Interventions
- DRUG methotrexate
- DRUG rituximab [MabThera/Rituxan]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 341 participants |
| Start Date | 2004-06 |
| Est. Completion | 2013-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02097745
The ClinicalTrials.gov registry entry for NCT02097745 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 341 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which methotrexate is the first listed.
NCT02097745 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02097745 about?
NCT02097745 is a clinical study titled "A Study of the Efficacy and Safety of Re-treatments With Rituximab in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-tnfa Therapies". This study will assess the long-term safety and efficacy of repeating treatment with MabThera, in combination with methotrexate and steroids, in patients who were previously randomized into MabThera study WA17042. The anticipated time on study treatment is until Mabthera is available on the local ma...
What is the current status of trial NCT02097745?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 341 participants. The study started on 2004-06. Estimated completion is 2013-06.
What interventions are being tested in trial NCT02097745?
The interventions under investigation include: methotrexate (DRUG), rituximab [MabThera/Rituxan] (DRUG).
Who is sponsoring clinical trial NCT02097745?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.